Migraine in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Migraine Major Market Overview
The Migraine market sales across the 7MM was $9.16 billion in 2023. The sales of migraine therapeutics across the 7MM will grow at a compound annual growth rate (CAGR) of more than 5% between 2023 and 2033. The launch of seven new pipeline products will drive growth in the migraine market across the 7MM.
Migraines are primary headaches, wherein the reoccurring headache is not a symptom caused by an underlying disease or condition. However, it is proposed that a complex interaction between genetics and environmental factors plays a large role in causing a migraine attack. The pain is often unilateral and pulsating in nature. It is usually also accompanied by photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.
Migraine Market Outlook, 2023-2033 ($ Billion)
Buy the Full Report to Know More about the Migraine Market Forecast
The Migraine market research report provides a granular forecast growth analysis for both global and regional markets through 2033. The report covers an exhaustive study of the countries wherein the market is prevalent, leading players, current treatment options, and factors driving the market growth. Furthermore, the pipeline valuation analysis and information on the market’s unmet needs and opportunities will help in determining potential business possibilities.
| Market Size (2023) | $9.16 billion |
| CAGR (2023-2033) | >5% |
| Forecast Period | 2023-2033 |
| Key Countries | · The US
· France · Germany · Italy · Spain · The UK · Japan |
| Key Classes | · Oral Triptan
· Nasal Triptan · Subcutaneous Triptan · Ergot Alkaloid · Anti-epileptic |
| Leading Players | · GlaxoSmithKline
· Merck · Pfizer · Abbvie · Novartis |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Migraine Market Segmentation by Countries
A few of the key countries wherein the migraine market is prevalent are the US, France, Germany, Italy, Spain, the UK, and Japan. In 2023, the US accounted for the highest migraine market share in the 7MM, due to the large migraine prevalent population, the high price of branded drugs, and the number of drugs marketed exclusively in the US compared to other countries in the 7MM.
Migraine Market Analysis by Countries, 2023 (%)
Buy the Full Report for More Country Insights into the Migraine Market
Migraine Market Segmentation by Classes
A few of the migraine classes in the US are oral triptan, nasal triptan, subcutaneous triptan, ergot alkaloid, and anti-epileptic, among others. In 2023, oral triptans accounted for the highest share of the migraine market.
Migraine Market Analysis by Classes, 2023 (%)
Buy the Full Report for More Class Insights into the US Migraine Market
Migraine Market - Competitive Landscape
A few of the major players in the Migraine market are:
- GlaxoSmithKline
- Merck
- Pfizer
- Abbvie
- Novartis
Migraine Market Analysis by Players
Buy the Full Report to Know More about Companies in the Migraine Market
Segments Covered in the Report
Migraine Country Outlook (Value, $ Billion, 2023-2033)
- The US
- France
- Germany
- Italy
- Spain
- The UK
- Japan
Migraine Class Outlook (Value, $ Billion, 2023-2033)
- Oral Triptan
- Nasal Triptan
- Subcutaneous Triptan
- Ergot Alkaloid
- Anti-epileptic
Scope
The report provides:
- Overview of migraine, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM migraine therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM migraine therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Dr. Reddy's Laboratories
OptiNose
Currax Pharmaceuticals
Tonix Pharmaceuticals
AstraZeneca
Endo Pharmaceuticals
Almirall
Viatris
Bausch Health Companies
IPI Legacy Liquidation Co
Supernus Pharmaceuticals
Upsher-Smith Laboratories
Sandoz
Merck & Co
Mallinckrodt
AbbVie
Johnson & Johnson
Eli Lilly
Amgen
Teva Pharmaceutical Industries
H. Lundbeck AS
Bristol-Myers Squibb
Axsome Therapeutics
Satsuma Pharmaceuticals
Amneal Pharmaceuticals
Klaria Pharma
Ipsen
Allodynic Therapeutics
Auden McKenzie
Lupin
Orion
Table of Contents
Frequently asked questions
-
What was the migraine market size across the 7MM in 2023?
The migraine market size across the 7MM was $9.16 billion in 2023.
-
What is the migraine market growth rate during the forecast period?
The migraine market is expected to achieve a CAGR of more than 5% during 2023-2033.
-
Which country had the highest share in the 7MM migraine market in 2023?
The US held the highest share in the migraine market across the 7MM in 2023.
-
Which migraine class had the highest share in the migraine market in 2023?
In 2023, oral triptan accounted for the highest share of the migraine market.
-
Which are the leading players operating in the chronic kidney disease market?
A few of the major players in the migraine market are GlaxoSmithKline, Merck, Pfizer, Abbvie, and Novartis, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Migraine reports



